Compare LODE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | LCTX |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 301.7M |
| IPO Year | 2004 | 1996 |
| Metric | LODE | LCTX |
|---|---|---|
| Price | $3.00 | $1.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $6.25 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,553,796.00 | ★ $14,556,000.00 |
| Revenue This Year | $1,582.85 | $109.40 |
| Revenue Next Year | $246.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $2.24 | $0.95 |
| 52 Week High | $4.98 | $2.09 |
| Indicator | LODE | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 28.98 |
| Support Level | $2.58 | N/A |
| Resistance Level | $3.45 | $1.32 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 10.49 | 2.81 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.